Clinical results using recombinant human platelet-derived growth factor and mineralized freeze-dried bone allograft in periodontal defects.
Human studies have demonstrated the safety and effectiveness of highly purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in combination with osteoconductive matrices for the treatment of moderate to severe periodontal intrabony defects. These study results, together with binding and release characteristics for rhPDGF-BB with different matrices, provide clear evidence that demineralized freeze-dried bone allograft and beta-tricalcium phosphate (beta-TCP) each can be combined with rhPDGF-BB to promote significant improvements in clinical, radiographic, and histologic parameters. The purpose of the current case series was to determine the clinical and radiographic regenerative potential of rhPDGF-BB-enhanced mineralized freeze-dried bone allograft (FDBA) for the treatment of severe periodontal intrabony defects. Clinical reentry and radiographs at up to 11 months showed complete bone fill in these challenging cases, indicating that rhPDGF combined with FDBA provides excellent clinical results.